초록

Bacterial infections may be treated using a high dosage regimen of amoxicillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.

대표청구항 ▼

1. A pharmaceutical formulation which provides a unit dosage of amoxicillin and potassium clavulanate, the formulation comprising in solid form from about 100 to 150 mg of potassium clavulanate and from about 1700 to 2500 mg of amoxicillin;wherein all of the potassium clavulanate and from 0 to 50% o

1. A pharmaceutical formulation which provides a unit dosage of amoxicillin and potassium clavulanate, the formulation comprising in solid form from about 100 to 150 mg of potassium clavulanate and from about 1700 to 2500 mg of amoxicillin;wherein all of the potassium clavulanate and from 0 to 50% of the amoxicillin are contained in a first release phase; andfrom 50 to 100% of the amoxicillin is in a second release phase; such that the composition when administered to a human, has a T>MIC is at least 4 hours for an MIC of 8 μg/ml. 2. A formulation according to claim 1 in which the unit dosage comprises about 125 mg of potassium clavulanate. 3. A formulation according to claim 1 in which the unit dosage comprises from 1900 to 2250 mg of amoxicillin. 4. A formulation according to claim 1 in which the unit dosage comprises about 2000 mg of amoxicillin. 5. A formulation according to claim 1 in which the second release phase comprises from 60 to 90% of the total amoxicillin content. 6. A formulation according to claim 1 in which the second release phase comprises from 70 to 90% of the total amoxicillin content. 7. A formulation according to claim 1 in which the second release phase comprises from 76 to 90% of the total amoxicillin content. 8. A formulation according to claim 1 in which mean T>MIC is at least 4.2 hours. 9. A formulation according to claim 1 in which mean T>MIC is at least 4.4 hours. 10. A formulation according to claim 1 in which mean T>MIC is at least 4.6 hours. 11. A formulation according to claim 1 in which mean T>MIC is at least 4.8 hours. 12. A formulation according to claim 1 in which the unit dosage is selected from 1750/125, 2000/125, and 2250/125 mg of amoxicillin and potassium clavulanate, respectively. 13. A formulation according to claim 1 in which the unit dosage is selected from a single monolith tablet, from 2 to 4 monolith tablets, a single bilayered tablet, or from 2 to 4 bilayered tablets. 14. A formulation according to claim 1 in which the unit dosage is provided as 2 tablets comprising about 1000/62.5 mg amoxicillin/potassium clavulanate. 15. A pharmaceutical formulation of amoxicillin and potassium comprising a composition in a solid form of from about 50 to 75 mg of potassium clavulanate and from about 850 to 1250 mg of amoxicillin; or from about 100 to 150 mg of potassium clavulanate and from about 1700 to 2500 mg of amoxicillin wherein all of the potassium clavulanate and from 0 to 60% of the amoxicillin is in a first release phase and from 40 to 100% of the amoxicillin is in a second release phase; which upon administration to a human provides a T>MIC of at least 4 hours for an MIC of 8 βg/ml. 16. A pharmaceutical formulation according to claim 15 which is a layered tablet formulation comprising the first release phase in a first layer, and the second release phase in a second layer. 17. A pharmaceutical formulation according to claim 16 in which the second release layer comprises at least one release retarding excipient selected from pH sensitive polymers; release-retarding polymers which have a high degree of swelling in contact with water or aqueous media such as the stomach contents; polymeric materials which form a gel on contact with water or aqueous media; and polymeric materials which have both swelling and gelling characteristics in contact with water or aqueous media. 18. A pharmaceutical formulation according to claim 17 in which release retarding excipient is xanthan gum present in front about 4 to 15% by weight of the layer. 19. A pharmaceutical formulation according to claim 16 in which the second release layer comprises a pharmaceutically acceptable soluble salt of amoxicillin and at least one pharmaceutically acceptable organic acid which are admixed, as solids, in intimate contact at a ratio of from about 20:1 to about 1:2 (amoxicillin free acid equivalent to organic acid equivalent). 20. A pharmaceutical formulation according to cl aim 19 in which pharmaceutically acceptable organic acid is a fruit acid. 21. A method of treating a bacterial infection in a patient in need thereof which method comprises administering an effective amount of a formulation according to claim 1 to said patient about every 12 hours. 22. A pharmaceutical formulation according to claim 18 wherein the xanthan gum is present in an amount from about 5% to about 10% by weight of the layer. 23. A pharmaceutical formulation according to claim 19 in which the soluble salt of amoxicillin is sodium amoxycillin. 24. A pharmaceutical formulation according to claim 19 in which the soluble salt of amoxicillin is crystallized sodium amoxycillin. 25. A pharmaceutical formulation according to claim 19 wherein the at least one pharmaceutically acceptable organic acid is selected from pharmaceutically acceptable monocarboxylic acid and polycarboxylic acid having from 2 to 10 carbon atoms and an acidic salt of any of the foregoing. 26. A pharmaceutical formulation according to claim 19 wherein the at least one pharmaceutically acceptable organic acid is selected from C (2-10) alkyl- and C (2-10) alkenyl-carboxylic acids having one, two, or three carboxylic acid groups, and optionally at least one hydroxy substituent, and optionally at least one —CO group in the carbon chain and an acidic salt of any of the foregoing. 27. A pharmaceutical formulation according to claim 26 wherein the at least one pharmaceutically acceptable organic acid is selected from malonic acid, succinic acid, fumaric acid, maleic acid, adipic acid, lactic acid, levulinic acid, sorbic acid, tartaric acid, malic acid, ascorbic acid, citric acid, and an acidic salt of any of the foregoing. 28. A pharmaceutical formulation according to claim 20 wherein the fruit acid is tartaric acid, malic acid, ascorbic acid or citric acid. 29. A pharmaceutical formulation according to claim 20 wherein the fruit acid is citric acid. 30. A pharmaceutical formulation according to claim 20 wherein the fruit acid is anhydrous citric acid. 31. A pharmaceutical formulation according to claim 23 wherein the pharmaceutically acceptable organic acid is citric acid. 32. A pharmaceutical formulation according to claim 23 wherein the pharmaceutically acceptable organic acid is anhydrous citric acid. 33. A pharmaceutical formulation according to claim 24 wherein the fruit acid is citric acid. 34. A pharmaceutical formulation according to claim 24 wherein the fruit acid is anhydrous citric acid. 35. A pharmaceutical formulation according claim 15 wherein the first release phase comprises at least one pharmaceutically acceptable soluable salt of amoxicillin. 36. A pharmaceutical formulation according to claim 35 wherein the soluable salt is amoxicillin trihydrate, or a mixture thereof. 37. A pharmaceutical formulation according claim 15 wherein the the first release phase comprises at least one pharmaceutically acceptable soluble salt of amoxicillin; and the second release phase comprises a soluble salt of amoxicillin and at least one pharmaceutically acceptable organic acid. 38. A pharmaceutical formulation according to claim 37 wherein the soluble salt of amoxicillin in the first release phase is amoxicillin trihydrate, or a mixture thereof. 39. A pharmaceutical formulation as claimed in claim 37 in which the soluable salt of amoxicillin in the second release phase is sodium amoxycillin. 40. A pharmaceutical formulation as claimed in claim 37 which the soluble salt of amoxicillin in the second release phase is crystallized sodium amoxycillin. 41. A pharmaceutical formulation as claimed in claim 37 wherein the at least one pharmaceutically acceptable organic acid is selected from pharmaceutically acceptable monocarboxylic acid and polycarboxylic acid having from 2 to 10 carbon atoms and an acidic salt of any of the foregoing. 42. A pharmaceutical formulation according to claim 37 wherein the at least one pharmaceutically acceptable organic acid is se lected from malonic acid, succinic acid, fumaric acid, maleic acid, adipic acid, lactic acid, levulinic acid, sorbic acid, tartaric acid, malic acid, ascorbic acid, citric acid, and an acidic salt of any of the foregoing. 43. A pharmaceutical formulation according to claim 42 wherein the fruit acid is tartaric acid, malic acid, ascorbic acid or citric acid. 44. A pharmaceutical formulation according to claim 42 wherein the fruit acid is citric acid. 45. A pharmaceutical formulation according to claim 15 in which the second release phase comprises from 60% to 90% of the total amoxicillin content. 46. A pharmaceutical formulation according to claim 15 in which the second release phase comprises from 70 to 90% of the total amoxicillin content. 47. A pharmaceutical formulation according to claim 15 in which the second release phase comprises from 76% to 90% of the total amoxicillin content. 48. A pharmaceutical formulation according to claim 15 in which the mean T>MIC is at least 4.2 hours. 49. A pharmaceutical formulation according to claim 15 in which the mean T>MIC is at least 4.4 hours. 50. A pharmaceutical formulation according to claim 15 in which the mean T>MIC is at least 4.6 hours. 51. A pharmaceutical formulation according to claim 15 in which the mean T>MIC is at least 4.8 hours. 52. A pharmaceutical formulation according to claim 17 wherein the at least one release retarding excipient is selected from methylcelluloses, carboxymethylcelluloses, low-molecular weight hydroxypropylmethylcelluloses, low-molecular weight polyvinylalcohols, polyoxyethyleneglycols, and noncross-linked polyvinylpyrrolidones. 53. A pharmaceutical formulation according to claim 15 in which the unit dosage is provided as a single monolith tablet, from 2 to 4 monolith tablets, a single bilayered tablet, or from 2 to 4 bilayered tablets. 54. A pharmaceutical formulation according to claim 15 in which the unit dosage is provided as 2 tablets each comprising 1000/62.5 mg amoxicillin/potassium clavulanate or 4 tablets each comprising 500/33.25 mg amoxicillin/potassium clavulanate. 55. A pharmaceutical formulation according to claim 15 in which the unit dosage comprises from 1900 to 2250 mg of amoxicillin. 56. A pharmaceutical formulation according to claim 55 in which the unit dosage comprises about 2000 mg of amoxicillin. 57. A pharmaceutical formulation according to claim 15 in which the unit dosage is selected from 1750/125, 2000/125, and 2250/125 mg of amoxicillin and potassium clavulanate, respectively. 58. A pharmaceutical formulation according to claim 15 in which the second release phase comprises from 50% to 100% of the total amoxicillin content. 59. A pharmaceutical formulation according to claim 15 in which the first release phase comprises from 0% to 50% of the total amoxicillin content. 60. A pharmaceutical formulation according to claim 19 wherein the ratio of amoxicillin free acid equivalent to organic acid equivalent in the second phase is about 2:1 to about 1:1.2. 61. A pharmaceutical formulation according to claim 19 wherein the ratio of amoxicillin free acid equivalent to organic acid equivalent in the second phase is about 1:1. 62. A formulation according to claim 1 wherein the Area Under the Curve (“AUC”) (plasma concentration versus time) of the total amount of amoxicillin in the composition is substantially similar to at least 80% of the corresponding dosage of amoxycillin taken as an immediate release formulation over the same dosage period. 63. A pharmaceutical formulation according to claim 15 wherein the Area Under the Curve (“AUC”) (plasma concentration versus time) of the total amount of amoxicillin in the composition is substantially similar to at least 80% of the corresponding dosage of amoxycillin taken as an immediate release formulation over the same dosage period. 64. A pharmaceutical formulation according to claim 15 wherein the Area Under the Curve (“AUC” ) (plasma concentration versus time) of the total amount of amoxicillin in the composition is substantially similar to at least 90% of the corresponding dosage of amoxycillin taken as an immediate release formulation over the same dosage period. 65. A pharmaceutical formulation according to claim 15 wherein the Area Under the Curve (“AUC”) (plasma concentration versus time) of the total amount of amoxicillin in the composition is substantially similar to at least 100% of the corresponding dosage of amoxycillin taken as an immediate release formulation over the same dosage period. 66. A pharmaceutical formulation according to claim 15 wherein the Area Under the Curve (“AUC”) (plasma concentration versus time) of the total amount of amoxicillin in the composition is bioequivalent to the corresponding dosage of amoxycillin taken as an immediate release formulation over the same dosage period. 67. A pharmaceutical formulation according to claim 15 which produces upon administration a plasma Cmax value which is two times the MIC value. 68. A method according to claim 21 wherein the bacterial infection is caused by at least one of the organisms S. pneumoniae, H. influenzae, and M. catarrhalis. 69. A method according to claim 21 wherein the duration of therapy is from about 7 to about 14 days. 70. A method of treating a respiratory tract infection in a patient in need thereof, which method comprises administering an effective amount of a formulation according to claim 1 to said patient about every 24 hours. 71. A method according to claim 70 wherein the bacterial infection is caused by at least one of the organisms S. pneumoniae, H. influenzae, and M. catarrhalis. 72. A method according to claim 70 in which the respiratory tract infection is community acquired pneumoniae, acute exacerbation of chronic bronchitis, or acute bacterial sinusitis. 73. A method according to claim 70 wherein the duration of therapy is from about 7 to about 14 days. 74. A method of treating a bacterial infection in a patient in need thereof which method comprises administering an effective amount of a formulation according to claim 15 to said patient. 75. A method according to claim 74 in which the bacterial infection is caused by at least one of the organisms S. pneumoniae, H. influenzae, and M. catarrhalis. 76. A method according to claim 74 wherein the duration of therapy is from about 7 to about 14 days. 77. A method of treating a respiratory tract infection in a patient in need thereof, which method comprises administering an effective amount of a formulation according to claim 15 to said patient about every 24 hours. 78. A method according to claim 77 in which the bacterial infection is caused by at least one of the organisms S. pneumoniae, H. influenzae, and M. catarrhalis. 79. A method according to claim 77 in which the respiratory tract infection is community acquired pneumoniae, acute exacerbation of chronic bronchitis, or acute bacterial sinusitis. 80. A method according to claim 77 wherein the duration of therapy is from about 7 to about 14 days.